| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aminolevulinic acid (5-ALA) is primarily known for its role as a biosynthetic precursor to heme 5-ALA — 5-aminolevulinic acid (5-aminolevulinic acid; often administered as the hydrochloride salt) is an endogenous, small-molecule heme biosynthesis precursor used clinically as a pro-photosensitizer for tumor visualization and, when paired with an appropriate light source, photodynamic therapy (PDT). It is formally a drug/prodrug modality whose functional identity is to drive intracellular accumulation of the fluorescent porphyrin protoporphyrin IX (PpIX), enabling fluorescence-guided resection (notably high-grade glioma) and light-activated cytotoxicity in appropriately illuminated tissues. Standard abbreviations include 5-ALA, ALA; the key active photochemical mediator is PpIX. Tumor selectivity is primarily metabolic (differential porphyrin/heme pathway handling), rather than target-receptor binding, and clinical performance is strongly constrained by light penetration and local oxygen availability. Primary mechanisms (ranked):
Bioavailability / PK relevance: Route-locked. Oral ALA-HCl is used for intraoperative fluorescence in glioma with timed dosing prior to anesthesia/surgery; topical formulations are used for dermatologic PDT with local incubation followed by office-based illumination. Systemic exposure is clinically relevant for oral use (and photosensitivity risk), while topical use is primarily local with workflow defined by incubation + illumination. In-vitro vs systemic exposure relevance: Many “dark” in-vitro ALA studies use concentrations that are not directly exposure-matched to clinical plasma levels; the clinically dominant cytotoxic mechanism is typically light-triggered, PpIX-mediated photochemistry rather than concentration-only pharmacology. Clinical evidence status: Established clinical deployment as an adjunct optical imaging agent for fluorescence-guided resection of suspected high-grade glioma (approved) and as a photosensitizer precursor for dermatologic PDT (approved for actinic keratosis; additional indications vary by jurisdiction). Oncology PDT applications beyond these settings are heterogeneous and commonly investigational or center-specific. -ALA is used in medical therapies such as photodynamic therapy (PDT) for certain types of cancer and skin conditions.- Inside the cells, ALA enters the heme biosynthetic pathway and is converted to protoporphyrin IX (PpIX), a potent photosensitizer. -The light activates the accumulated PpIX, leading to the production of reactive oxygen species (ROS). -FDA approved June 2017 as a photo-imaging tool during neurosurgery for malignant glioma. The patient takes an oral dose of Gleolan 3 hours before surgery. Mechanistic pathway ranking for 5-ALA (oncology focus)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| (Also known as Hsp32 and HMOX1) HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene. HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer. -widely regarded as having antioxidant and cytoprotective effects -The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by: Reducing oxidative stress and inflammation Promoting angiogenesis (the formation of new blood vessels) Inhibiting apoptosis (programmed cell death) Enhancing cell migration and invasion When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions. A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1. -Curcumin Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects. -Resveratrol Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties. -Quercetin Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses. -EGCG Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties. -Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes. -Luteolin Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models. -Apigenin Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities. |
| 3453- | 5-ALA, | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:332 Target#:597 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid